HeartBeam Inc. (NASDAQ: BEAT) has announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia. This development represents a significant step in the company's efforts to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to fill a critical gap.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could revolutionize how we monitor and detect cardiac ischemia outside of clinical settings.”
The pilot study will evaluate the patch's ability to detect coronary artery disease and inadequate blood flow and oxygen supply to tissue. If successful, the technology could enable earlier diagnosis and intervention for patients with ischemic heart disease, potentially reducing the risk of heart attacks and other adverse cardiac events.
HeartBeam's patch is designed to be worn by patients over an extended period, providing continuous monitoring and the ability to capture ECG data on demand. This contrasts with traditional patch-based monitors, which typically lack the capability to perform a full 12-lead ECG, limiting their diagnostic utility. The company believes its technology could offer a more comprehensive solution for ambulatory monitoring.
The announcement comes as the seriousness of coronary artery disease continues to intensify with an aging population and increasing prevalence of cardiovascular risk factors. HeartBeam's study could provide valuable data on the clinical utility of its patch, potentially paving the way for regulatory submissions and commercial adoption.
For more information about HeartBeam and its technology, visit the company's newsroom at https://nnw.fm/BEAT. NetworkNewsWire, which distributed this press release, is a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. More information is available at https://www.NetworkNewsWire.com.
